World's First Oral Insulin for Type-2 Diabetes

China is set to become the world’s first country with oral insulin accessibility for type 2 diabetes, revealed report. After successfully completing Phase III trials of oral insulin, China's Hefei Tianhui Biotechnology (HTIT) submitted a //marketing authorisation application (MAA) to the country's National Medical Products Administration (1^✔ ✔Trusted Source
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Go to source).

Oral Insulin for Diabetes Treatment

"Oral insulin is a paradigm shift from the traditional injectable insulin market. Therefore, there would be a lot of opportunities and challenges in the commercialization of oral insulins," said Prashant Khadayate, Pharma Analyst at GlobalData, in a statement.

"Even though insulin delivery through injections has improved significantly for patients, compliance is always an issue for injectable forms of insulin. Hence, oral insulin will always be preferred, potentially reducing the discomfort associated with injections and thereby, improving overall compliance, provided it is equally effective in terms of efficacy and safety. Notably, it is difficult to comment on its efficacy and safety with injectable insulins as Phase III trials included only placebo," Khadayate added.

In November 2015, HTIT in-licensed exclusive rights to Oramed's oral insulin ORMD-0801 in China, Hong Kong, and Macau.

On the contrary, its partner Oramed terminated its oral insulin clinical trial activities in the US in T2D following disappointing results of the Phase III ORA-D-013-1 trial in January 2023.

Back in July 2006, Pfizer launched the world's first inhaled insulin, Exubera, but barely a year later, it withdrew Exubera from the market as it was not commercially successful.

Currently, there are only two oral insulins in Phase III globally. The number of diagnosed prevalent cases of Type 2 diabetes in China is estimated to grow at a CAGR of 2.21 percent from 57.4 million in 2022 to 63.3 million in 2028, as per GlobalData (2^✔ ✔Trusted Source
Type 2 Diabetes - Epidemiology Forecast to 2028

Go to source).

Advertisement

References:

1. Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China - (https://www.prnewswire.com/il/news-releases/oramed-announces-that-its-chinese-partner-htit-has-successfully-completed-a-phase-3-oral-insulin-clinical-trial-and-submitted-a-marketing-authorization-application-in-china-301824604.html)
2. Type 2 Diabetes – Epidemiology Forecast to 2028 - (https://www.globaldata.com/store/report/type-2-diabetes-epidemiology-forecast-to-2028/)

Source-IANS